A Bayesian meta-analysis of prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor in children with cancer.

The purpose of this analysis was to examine the efficacy of prophylactic hematopoietic colony-stimulating factors (CSFs) in pediatric cancer and to describe how a Bayesian meta-analysis can be conducted and then modified to incorporate information not readily included in a frequentist meta-analysis. Three Bayesian models were developed. The simplest model used the same data as a published frequentist meta-analysis. The second model included data that could not easily be incorporated into the frequentist meta-analysis, including data from different courses of chemotherapy and continuous outcomes that did not report variance estimates. The third model examined the effect of CSF type (granulocyte CSF vs. granulocyte-macrophage CSF). Compared with the frequentist model, the Bayesian model with the most data suggested a greater benefit of CSFs, with a 3.2-day reduction in duration of parenteral antibiotics (95% credible interval: -7.1, 0.7) in the expanded Bayesian model compared with a 0.8-day (95% confidence interval: -2.3, 0.7) reduction in the frequentist model. Bayesian meta-analysis also suggested that, compared with granulocyte-macrophage CSF, granulocyte CSF was associated with a 4.8-day decrease in the duration of parenteral antibiotics. Bayesian meta-analysis can readily include information not easily incorporated in a frequentist meta-analysis. Some treatment effect estimates were larger by a clinically important amount when additional data contributed to the pooled estimate.

[1]  A. Baruchel,et al.  Use of recombinant human granulocyte colony-stimulating factor to increase chemotherapy dose-intensity: a randomized trial in very high-risk childhood acute lymphoblastic leukemia. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Relling,et al.  Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia. , 1997, The New England journal of medicine.

[3]  Jill Hayden,et al.  Seven items were identified for inclusion when reporting a Bayesian analysis of a clinical study. , 2005, Journal of clinical epidemiology.

[4]  A. D. de Craen,et al.  Granulocyte-macrophage colony-stimulating factor (GM-CSF) ameliorates chemotherapy-induced neutropenia in children with solid tumors. , 1997, Pediatric hematology and oncology.

[5]  M. Schrappe,et al.  A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group. , 1996, Blood.

[6]  J. Shuster,et al.  Randomized trial of r-metHu granulocyte colony-stimulating factor in an intensive treatment for T-cell leukemia and advanced-stage lymphoblastic lymphoma of childhood: a Pediatric Oncology Group pilot study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Mark L. Greenberg,et al.  Concurrent RhGM‐CSF does not offset myelosuppression from intensive chemotherapy: Randomized placebo‐controlled study in childhood acute lymphoblastic leukemia , 1994, American journal of hematology/oncology.

[8]  S. Burdach,et al.  Granulocyte‐macrophage‐colony stimulating factor for prevention of neutropenia and infections in children and adolescents with solid tumors. Results of a prospective randomized study , 1995, Cancer.

[9]  E. Bouffet,et al.  An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma. , 1998, European journal of cancer.

[10]  F. Dunstan,et al.  Granulocyte colony-stimulating factor ameliorates toxicity of intensification chemotherapy for acute lymphoblastic leukemia. , 1999, Medical and pediatric oncology.

[11]  C. R. Pinkerton,et al.  A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. , 2002, Medical and pediatric oncology.

[12]  S. Steinberg,et al.  Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Two cheers for Bayes. , 1996, Controlled clinical trials.

[14]  K. Welte,et al.  HAEMATOPOIETIC GROWTH FACTORS IN CHILDREN WITH NEUTROPENIA , 2002, British journal of haematology.

[15]  A. Berger FUNDAMENTALS OF BIOSTATISTICS , 1969 .

[16]  B. Bloom,et al.  Classic or Bayesian research design and analysis. Does it make a difference? , 2002, International journal of technology assessment in health care.

[17]  P. Riikonen,et al.  Prophylactic administration of granulocyte colony‐stimulating factor (filgrastim) after conventional chemotherapy in children with cancer , 1995, Stem cells.

[18]  A. Baruchel,et al.  Granulocyte colony-stimulating factor in induction treatment of children with non-Hodgkin's lymphoma: a randomized study of the French Society of Pediatric Oncology. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  P. Nathan,et al.  Prophylactic granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor decrease febrile neutropenia after chemotherapy in children with cancer: a meta-analysis of randomized controlled trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  S. Jhanwar,et al.  Human Granulocyte Colony-Stimulating Factor in Children With High-Risk Acute Lymphoblastic Leukemia: A Children’s Cancer Group Study , 2003 .

[21]  R. Ragusa,et al.  Assessment of the value of treatment with granulocyte colony‐stimulating factor in children with acute lymphoblastic leukemia: a randomized clinical trial , 1995, European journal of haematology.

[22]  Gareth O. Roberts,et al.  Convergence assessment techniques for Markov chain Monte Carlo , 1998, Stat. Comput..